Amgen Presents P-III (FOURIER) OLE Results of Repatha (evolocumab) for Atherosclerotic Cardiovascular Disease at ESC 2022, Published in Circulation
Shots:
- The P-III (FOURIER) OLE studies evaluate the safety & tolerability of Repatha vs PBO in 6,635 patients with ASCVD for a median follow-up of ~5yrs.
- The results showed a significant & sustained reduction in LDL-C levels with 80% of patients achieving an LDL-C level of <55mg/dL, LDL-C reduction of 58% from baseline was consistent over long-term follow-up (260wk.) with no new safety results
- In an additional prespecified exploratory analysis, the therapy showed a lower rate of major adverse CV events, incl. CV death with 20% relative risk reduction for major CV & 23% RRR for CV death. The company will share the results with the regulatory authority & the therapy is being evaluated in (VESALIUS-CV) trial
Ref: Amgen | Image: Amgen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.